Carly Tymm

Dr. Carly Tymm

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2020 in Cellular and Molecular Bioengineering
Verified
Journal Article
Closed access
PDF file
CTCarly Tymm
Carly Tymm
JZJunhu Zhou
Junhu Zhou
ATAmogha Tadimety
Amogha Tadimety
ABAlison Burklund
Alison Burklund
JZJohn X. J. Zhang
John X. J. Zhang

11 October 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
ZZZexian Zeng
Zexian Zeng
SGShengqing Stan. Gu
Shengqing Stan. Gu
NONofal Ouardaoui
Nofal Ouardaoui
CTCarly Tymm
Carly Tymm
LYLin Yang
Lin Yang
XLX. Shirley Liu
X. Shirley Liu
MHC-II is known to be mainly expressed on the surface of antigen-presenting cells. Evidence suggests MHC-II is also expressed by cancer cells and may be associated with better immunotherapy responses. However, the role and regulation of MHC-II in cancer cells remain unclear. In this study, we leveraged data mining and experimental validation to elucidate the regulation of MHC-II in cancer cells and its role in modulating the response to immunotherapy. We collated an extensive collection of omics data to examine cancer cell–intrinsic MHC-II expression and its association with immunotherapy outcomes. We then tested the functional relevance of cancer cell–intrinsic MHC-II expression using a syngeneic transplantation model. Finally, we performed data mining to identify pathways potentially involved in the regulation of MHC-II expression, and experimentally validated candidate regulators. Analyses of preimmunotherapy clinical samples in the CheckMate 064 trial revealed that cancer cell–intrinsic MHC-II protein was positively correlated with more favorable immunotherapy outcomes. Comprehensive meta-analyses of multiomics data from an exhaustive collection of data revealed that MHC-II is heterogeneously expressed in various solid tumors, and its expression is particularly high in melanoma. Using a syngeneic transplantation model, we further established that melanoma cells with high MHC-II responded better to anti–PD-1 treatment. Data mining followed by experimental validation revealed the Hippo signaling pathway as a potential regulator of melanoma MHC-II expression. In summary, we identified the Hippo signaling pathway as a novel regulator of cancer cell–intrinsic MHC-II expression. These findings suggest modulation of MHC-II in melanoma could potentially improve immunotherapy response.

26 November 2020 in Chemistry of Materials
Verified
Journal Article
Closed access
NBNicholas D. Blelloch
Nicholas D. Blelloch
HMHaydn T. Mitchell
Haydn T. Mitchell
CTCarly Tymm
Carly Tymm
DCDouglas W Van Citters
Douglas W Van Citters
KMKatherine Mirica
Katherine Mirica

17 December 2024 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
CTCarly Tymm
Carly Tymm
RVReena M. Vattakalam
Reena M. Vattakalam
DFDavid R. Flum
David R. Flum
JWJason D. Wright
Jason D. Wright
KFKatherine N. Fischkoff
Katherine N. Fischkoff

14 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DPDaniel M. Portnoy
Daniel M. Portnoy
MPMatthieu Paiola
Matthieu Paiola
CTCarly Tymm
Carly Tymm
RWRobert Winchester
Robert Winchester
AMAdam Mor
Adam Mor
YGYevgeniya Gartshteyn
Yevgeniya Gartshteyn
Osteoarthritis (OA) is the most prevalent form of arthritis and is a major global health burden. OA is a heterogeneous condition with multiple contributing mechanisms that characterize different subtypes and stages of the disease. In this review, we examine the insights gained into the immunological characteristics of OA that have emerged from the increasingly widespread use of checkpoint inhibitors in the immunotherapy of malignancies. We discuss how the conventional view of OA as a degenerative disease is changing in view of the evidence suggesting that OA has an inflammatory component along with the presence in joint tissue of peripherally tolerized autoreactive resident memory T cells, which upon release of their inhibition by immunotherapy mediate immune-related adverse event arthritis (irAE-arthritis). We review clinical trials evaluating the efficacy of immunosuppressive therapies in modifying the course of OA, thereby providing an additional perspective on the presence and nature of the inflammation in OA. In summary, we argue that a shift from the traditional understanding of OA as a mechanical disease to one that incorporates the role of synovial immune cells and mechanisms of self-tolerance is necessary to guide future therapies, including the use of immune checkpoints for patients with OA.